GH1 and Fanconi anemia: Tables 3, 4 describe these studies, where Table 3 also includes patients treated with GH beyond the CCS cohort. Unfortunately the existing studies exclude those with cancer predisposition syndromes (e.g. Fanconi anemia, Bloom syndrome, Li-Fraumeni syndrome, Lynch syndrome) and so a consensus about GH treatment in this population does not exist. This population is of particular interest as they include disorders of DNA damage/repair, and as growth factors, GH and IGF-1 may reduce time for DNA repair by promoting progression of the cell cycle (76).